Asia Pacific Schizophrenia Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, and First- Generation Antipsychotics), By Route of Administration (Oral Antipsychotics and Injectable Antipsychotics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Asia Pacific Schizophrenia Drugs Market Insights, Industry Trend, Forecasts to 2035

Asia Pacific Schizophrenia Drugs Market Size Insights Forecasts to 2035

• The Market Size is Expected to Grow at a CAGR of around 5.8% from 2025 to 2035
• The Asia Pacific Schizophrenia Drugs Market Size is Expected to hold a significant share by 2035

According to a Research Report Published by Spherical Insights & Consulting, the Asia Pacific Schizophrenia Drugs Market Size is anticipated to hold a significant share by 2035, growing at a CAGR of 5.8% from 2025 to 2035. The Asia Pacific schizophrenia drugs market is fueled by next-generation antipsychotics and growing mental health support that are reshaping schizophrenia care, improving outcomes with fewer side effects. Combined with an aging population and robust drug pipeline, these trends strongly support sustained market growth.

Market Overview

The Schizophrenia Drugs Market Size is the market of drugs used for treating severe and long-lasting mental illness. Schizophrenia alters a person's thoughts, feelings, and behaviors and frequently results in a loss of reality awareness. It usually manifests in late adolescence or early adulthood and is typified by psychotic episodes that include delusions, hallucinations, disordered thinking, and impaired functioning. Despite affecting fewer than 1% of adults in the United States, it is one of the most incapacitating mental diseases.  Schizophrenia cannot be cured, but it can be controlled with medicine, counseling, and support networks.

During the COVID-19 epidemic, the market for schizophrenia suffered because of restricted access to diagnostic and treatment services. But as awareness grows and healthcare services resume, the market is recovering. The need for efficient treatment alternatives is being driven by rising prevalence worldwide, especially among the elderly population. Market expansion is also being aided by government programs and more R&D expenditures. All things considered, the increased emphasis on mental health and better healthcare facilities should support sustained market growth.

Report Coverage

This research report categorizes the market for Asia Pacific schizophrenia drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific schizophrenia drugs market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific schizophrenia drugs market.

Driving Factors

The next-generation antipsychotics with improved efficacy and fewer side effects are revolutionizing the treatment of schizophrenia due to continuous advancements in pharmaceutical research. A major step toward increasing therapeutic alternatives has been taken with the recent approval of innovative medications like Cobicistat. Improved access to care, greater mental health awareness, and government assistance are all contributing to an increase in diagnoses and prescription use. The patient base is significantly expanded by the aging population, especially for late-onset schizophrenia.  A solid basis for market expansion is being established by these tendencies. The strong medication pipeline indicates that effective and individualized treatment for schizophrenia will continue to progress.

Restraining Factors

The market growth is hindered by the antipsychotic medication side effects, and safety issues are still impeding the expansion of the schizophrenia market. Low adherence and relapse are frequently caused by problems such as metabolic abnormalities and poor tolerability. Even more recent therapies, like COBENfy, have significant adverse effects that need constant observation. A major obstacle preventing wider adoption and market expansion is still striking a balance between safety and efficacy.

Market Segmentation

The Asia Pacific schizophrenia drugs market share is classified into drug class, route of administration, and distribution channel.

• The second-generation antipsychotics segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

The Asia Pacific schizophrenia drugs market is segmented by drug class into second-generation antipsychotics, third-generation antipsychotics, and first-generation antipsychotics. Among these, the second-generation antipsychotics segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. This is attributed to the safety and effectiveness of second-generation antipsychotics over first-generation antipsychotics, and their demand is growing. Better patient compliance results from these newer drugs' decreased risk of movement-related side effects, like tremors and rigidity. Long-acting injectable formulations of second-generation antipsychotics make them more appealing, and they are also utilized for diseases such as treatment-resistant depression.

• The injectable antipsychotics segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific schizophrenia drugs market is segmented by route of administration into oral antipsychotics and injectable antipsychotics. Among these, the injectable antipsychotics segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is due to the injectable formulations, especially long-acting injectables (LAIs), which can overcome typical obstacles in the treatment of schizophrenia, and there is a rising preference for them. By ensuring steady plasma levels and consistent medication release, LAIs lower the chance of relapse brought on by skipping oral doses. Compared to daily oral drugs, this delivery route requires less frequent administration, which improves treatment adherence.

• The hospital pharmacies segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific schizophrenia drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, the hospital pharmacies segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is due to the hospital pharmacist’s crucial role in providing comprehensive patient care by overseeing complicated drug regimens and keeping an eye out for side effects. They are important distributors of cutting-edge medicines since they have easy access to experimental medications and novel drugs. Better results are obtained when hospital pharmacies are integrated with other medical services to improve patient care continuity.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific schizophrenia drugs market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Eli Lilly and Company
• Sumitomo Dainippon Pharma
• AstraZeneca
• AllerganVanda Pharmaceuticals
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific schizophrenia drugs market based on the following segments:

Asia Pacific Schizophrenia Drugs Market, By Drug Class

• Second-Generation Antipsychotics
• Third-Generation Antipsychotics
• First-Generation Antipsychotics

Asia Pacific Schizophrenia Drugs Market, By Route Of Administration

• Oral Antipsychotics
• Injectable Antipsychotics

Asia Pacific Schizophrenia Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others